Swipe to the right

How does BPC-157 help balance dopamine, cardiovascular function, and healing?

“product By Nemo 2 months ago

"Stable gastric pentadecapeptide BPC 157 is an anti-ulcer peptidergic agent, safe in inflammatory bowel disease clinical trials (GEPPPGKPADDAGLV, M.W. 1419, PL 14736) and wound healing, stable in human gastric juice, with no toxicity being reported... it has a prominent effect on alcohol-lesions (i.e. acute, chronic) and NSAIDs lesions (interestingly, BPC 157 both prevents and reverses adjuvant arthritis)... It has strong angiogenic potential, acts protectively on endothelium, prevents and reverses thrombus formation after abdominal aorta anastomosis, affects many central disturbances (i.e. dopamine and 5-HT system)... acts as free radical scavenger... and exhibits neuroprotective properties. BPC 157 successfully heals the intestinal anastomosis, gastrocutaneous, duodenocutaneous and colocutaneous fistulas in rats, as well as interacting with the NO system. Interestingly, the fistula closure was achieved even when the BPC 157 therapy was postponed for one month." (5)


Multi-Organ Membrane Repair and Dopamine Balancing.

"Pentadecapeptide BPC 157 antagonises the incidence of a series of gastrointestinal lesions, it has a positive impact on the healing processes of various wounds, a proven angiogenic effect, protective effect on endothelium and it modulates synthesis of NO." (1)

"Apart from the effects on various gastrointestinal lesions, the potentially beneficial effect on pancreas, liver injuries, endothelium and heart damage, i.e. dysrhythmias following reoxygenation, and blood pressure, along with effect on experimental acute/chronic inflammation, wound and fracture (pseudoarthrosis) healing are described. It appears that these beneficial effects all together provide a particular network reflecting activity of a special peptidergic defence system." (4)

"In support of this concept, it appears that there are interactions of this pentadecapeptide with many important systems (namely, dopamine-, NO-, prostaglandin-, somatosensory neurone-systems), that could provide a basis for the observed protective effects. Moreover, since disturbance of these systems' functions (i.e. dopamine-, NO-, somatosensory neuronal-system) which manifest either over-activity or as inhibition, may contribute to the multiple lesions in different organs. The reported evidence that this pentadecapeptide is able to counteract both their over-action, and their inhibition, may suggest this pentadecapeptide as a new, but most probably essential physiological defence system and that should be further investigated." (4)

File:Gastric Ulcer.png


Reducing Lung Failure and Right Ventricle Enlargement of Heart.

"In this study, when administered intraperitoneally from Days 1-29, BPC 157 inhibited the development of muscularization and hypertrophy of the media in pulmonary arteries, it prevented pulmonary hypertension and the right heart hypertrophy and failure... Moreover, the death rate significantly decreased in those animals treated with BPC 157." (1) "Isoprenaline myocardial infarction suitably mimicks human myocardial ischemia. As an anti-ulcer peptide that also improves wound healing (including transected muscle), BPC 157 was shown as safe in trials for inflammatory bowel disease (PL14736, Pliva). This peptide also showed positive effect in heart failure model induced by doxorubicine and heart arryhthmias induced by hypoxic and reoxygenation injury." (2)

"This study has demonstrated protective effect of pentadecapeptide BPC 157 on mycardial infarction induced by isoprenaline in rats and its potentional clinical application in treatment of ishemic heart disease. The results of this study are in accord with previously demonstrated protective effect on endothelial cells and induction of NO by this peptide in various organ's leasons." (2)


Counteraction of Arrhythmia and Both High and Low Blood Pressure.

"BPC 157 furthermore reduces the duration of arrhythmias induced by ischemic-reperfusional injury in the isolated pig heart..." (1)

"...counteraction of both the L-arginine-induced disturbance and L-NAME-induced disturbance was seen, while maintaining blood pressure against both L-arginine (hypotension) and L-NAME (hypertension) (note, BPC 157 by itself does not affect basal blood pressure values [25] and likewise, BPC 157 by itself does not affect basal coagulation/platelets values." (3)

"Pentadecapeptide BPC 157 Reduces Bleeding and Thrombocytopenia [low blood platelet count, which can lead to blood clotting] after Amputation in Rats Treated with Heparin, Warfarin, L-NAME and L-Arginine" (3)

File:Illustration of an enlarged heart (Cardiomegaly).png


Sourcing Studies:

(1) Sikiriê, P., Udoviëiê, M., Bariπiê, I., Balenoviê, D., Uzun, S., Striniê, D., Lovriê Benëiê, M. and Seiwerth, S. (n.d.). BPC 157 prevents development of MCT-induced pulmonary hypertension and cor pulmonale in rats. [online] Available at: https://pdfs.semanticscholar.org/8e4f/6200d548e93be1df56f72610f790c59a23f0.pdf

(2) Barišić, I., Radić, B., Kliček, R., Sever, M., Ilić, S., Bilić, V., Berkopić, L., Udovičić, M., Filipović, M., Brčić, L., Brčić, I., Kolenc, D., Lovrić-Benčić, M., Seiwerth, S. and Sikirić, P. (2010). Effect of pentadecapeptide BPC 157 on myocardial infarction in rat induced by isoprenaline hydrochloride. Abstracts of the 13th International conference on gastrointestinal research & 13th International conference on on ulcer research ; u: Journal of physiology and pharmacology, [online] p.9. Available at: https://www.bib.irb.hr/467800

(3) Stupnisek, M., Kokot, A., Drmic, D., Hrelec Patrlj, M., Zenko Sever, A., Kolenc, D., Radic, B., Suran, J., Bojic, D., Vcev, A., Seiwerth, S. and Sikiric, P. (2015). Pentadecapeptide BPC 157 Reduces Bleeding and Thrombocytopenia after Amputation in Rats Treated with Heparin, Warfarin, L-NAME and L-Arginine. PLoS ONE, [online] 10(4). Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405609/

(4) P, S. (1999). The Pharmacological Properties of the Novel Peptide BPC 157 (PL-10). [online] Inflammopharmacology. Available at: https://pubmed.ncbi.nlm.nih.gov/17657443/

(5) Sikiric, P., Seiwerth, S., Rucman, R., Turkovic, B., Rokotov, D.S., Brcic, L., Sever, M., Klicek, R., Radic, B., Drmic, D., Ilic, S., Kolenc, D., Vrcic, H. and Sebecic, B. (2011). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, [online] 17(16), pp.1612–1632. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21548867


Product available for research use only:

BPC-157

Posted in: BPC-157